Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Short term Debt (2022 - 2025)

Historic Short term Debt for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $70.0 million.

  • Axsome Therapeutics' Short term Debt rose 76090.27% to $70.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year increase of 76090.27%. This contributed to the annual value of $8.3 million for FY2024, which is 2931.17% up from last year.
  • Axsome Therapeutics' Short term Debt amounted to $70.0 million in Q3 2025, which was up 76090.27% from $70.0 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Short term Debt registered a high of $70.0 million during Q2 2025, and its lowest value of $5.9 million during Q4 2022.
  • Moreover, its 4-year median value for Short term Debt was $6.8 million (2022), whereas its average is $15.9 million.
  • Its Short term Debt has fluctuated over the past 5 years, first plummeted by 468.57% in 2023, then skyrocketed by 89431.82% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Short term Debt (Quarter) stood at $5.9 million in 2022, then grew by 8.59% to $6.4 million in 2023, then grew by 29.31% to $8.3 million in 2024, then soared by 744.9% to $70.0 million in 2025.
  • Its Short term Debt was $70.0 million in Q3 2025, compared to $70.0 million in Q2 2025 and $8.6 million in Q1 2025.